Bayer HealthCare

Divisions of Bayer HealthCare

• More information about the four divisions of Bayer HealthCare

Sales 2008

Sales of the HealthCare subgroup grew by 3.8 percent in 2009, to € 15,988 million. Adjusted for currency and portfolio effects, sales climbed by 3.8 percent. The increase was due to the positive business performance of both segments.

• Our 20 best-selling products in 2009

Performance 2009

Sales of our Pharmaceuticals segment increased by 4.4 percent in 2009 to €10,467 million (2008: €10,030 million). Adjusted for currency and portfolio effects, sales advanced by 4.8 percent. Business expanded encouragingly in the Asia/Pacific (Fx adj. +9.1 %) and Latin America/Africa/Middle East (Fx adj. +12.7 %) regions, more than offsetting the slight decline in North America (Fx adj. -1.9 %)

Our Consumer Health segment improved by 2.7 percent to €5,521 million (2008: €5,377 million). Adjusted for currency and portfolio effects, business was up by 2.1 percent, with all divisions contributing to this increase. This performance was due chiefly to strong sales gains in Russia and China that offset weaker business in the United States.

In the Consumer Care Division, sales advanced by 2.0 percent to €3,080 million (2008: €3,020 million). The currency- and portfolio-adjusted increase was 2.5 percent. The effects of the economic weakness in established markets were more than offset by solid growth in the emerging markets. We achieved sales gains particularly for the food supplement lines Redoxon® (Fx adj. +19.1 %) and Berocca® (Fx adj. +13.6 %). Furthermore, our Bepanthen®/Bepanthol® skincare products (Fx adj. +10.3 %) performed well, particularly in Europe. By contrast, sales were down for our analgesic Aspirin® (Fx adj. -9.3 %) due to inventory adjustments in the market and intensified competition.

Sales of the Medical Care Division expanded by 5.0 percent to €1,464 million (2008: €1,394 million). The currency- and portfolio-adjusted increase was 2.1 percent. This growth was based primarily on higher sales of our blood glucose meters. Our Contour® product line (Fx adj. +7.3 %) performed particularly well in Europe. This expansion was due in part to the substitution of our older Elite® system (Fx adj. -30.5 %), which generated sales of €83 million in 2009. The decline in business with our Breeze® multi-test system (Fx adj. -7.4 %) was attributable to an economy-related drop in demand in the United States.

In the Animal Health Division, sales advanced by 1.5 percent to €977 million (2008: €963 million). Adjusted for currency effects, the increase came to 1.0 percent. Business with our antiparasitic agent Baycox® grew by 15.6 percent (Fx adj.) to €48 million, mostly as a result of its market launch in Japan. Sales of our Advantage ® line of flea, tick and worm control products remained level year on year, with the positive trend in the United Kingdom and Australia offsetting declines in the United States. Generic competition in Europe diminished sales of our Baytril® board-spectrum antibiotic (Fx. -4.7 %)

Research & Development 2009

In 2009 we invested €1,847 million (2008: €1,742 million) in research and development in the Pharmaceuticals and Consumer Health segments to lay the foundations for the introduction of further innovative products in the subgroup’s expanding markets. This represented about 67.3 percent of the Bayer Group’s entire research and development expenditures and was equivalent to 11.6 percent of sales.

• More information about Research & Development

More information

 

• The four divisions of Bayer HealthCare
• Our 20 best-selling products in 2009
• More information about Research & Development of our divisions